Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleMIT Technology Review

Treating enterprise AI as an operating layer

View original at technologyreview.com
MIT Technology Review - Ai Research Title: Treating enterprise AI as an operating layer Date: 2026-04-16 13:00 Source: https://www.technologyreview.com/2026/04/16/1135554/treating-enterprise-ai-as-an-operating-layer/ <p>There’s a fault line running through enterprise AI, and it’s not the one getting the most attention…
Opening lines of the source · MIT Technology Review · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The prevailing narrative says nimble startups will out-innovate incumbents by building AI-native from scratch. If AI is primarily a model problem, that story holds. But in many enterprise domains, AI is a systems problem—integrations, permissions, evaluation, and change management—where advantage accrues to whomever already sits inside high-volume, high-stakes operations.

    60% confidence
  • The goal is to permanently embed the accumulated expertise of thousands of domain experts—their knowledge, decisions, and reasoning—into an AI platform that amplifies what every operator can accomplish, producing a quality of execution that neither humans nor AI achieve independently.

    60% confidence
  • Model providers like OpenAI and Anthropic sell intelligence as a service that is highly capable and increasingly interchangeable. The distinction that matters is whether intelligence resets on every prompt or accumulates over time.

    60% confidence
  • An AI-native platform inverts traditional architecture by ingesting a problem, applying accumulated domain knowledge, executing autonomously what it can with high confidence, and routing targeted sub-tasks to human experts when the situation demands judgment that the system can't yet reliably provide.

    60% confidence
  • If an organization processes 50,000 cases a week and captures just three high-quality decision points per case, that's 150,000 labeled examples every week without creating a separate data-collection program.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com